Impact Biomedical director disposes of 4,170 shares

Jason Grady reported disposition transactions in this Form 4 filing.

Available on EDGAR 11/05/2026 - 05:48 PM EST Accepted by SEC EDGAR 11/05/2026 - 05:48 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Jason Grady reported disposition transactions in this Form 4 filing. Impact Biomedical Inc. director Jason Grady reported a transaction involving 4,170 shares of common stock dated October 7, 2026, described as a reward under the company's 2023 Employee, Director and Consultant Equity Incentive Plan. The reported price was $4.54 per share; his direct common-stock holdings following the transaction were 28,164 shares.

Insider Trade Summary

Grant/Award: 4,170 shares

Grant/Award 1 txn

Insider Grady Jason

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,170	$4.54	$19K

Holdings After Transaction: Common Stock — 28,164 shares (Direct)

Key Figures

Transaction shares: 4,170 shares Reported price per share: $4.54 per share Direct holdings following transaction: 28,164 shares

3 metrics

Transaction shares 4,170 shares October 7, 2026; described as a reward under the company's 2023 Employee, Director and Consultant Equity Incentive Plan

Reported price per share $4.54 per share Transaction dated October 7, 2026

Direct holdings following transaction 28,164 shares Jason Grady's reported common-stock holdings after the October 7, 2026 transaction

Key Terms

Equity Incentive Plan

1 terms

Equity Incentive Plan financial

"2023 Employee, Director and Consultant Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IBO shares were involved in Jason Grady's reported transaction?

Jason Grady reported a transaction involving 4,170 shares of common stock on October 7, 2026, associated with the company's 2023 Employee, Director and Consultant Equity Incentive Plan; his direct holdings afterward were 28,164 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grady Jason

(Last) (First) (Middle)

275 WIREGRASS PKWY

(Street)

HENRIETTA NEW YORK 14586

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMPACT BIOMEDICAL INC. [ IBO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/07/2026		A		4,170	D	$4.54	28,164	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Reward pursuant to Impact BioMedical Inc.'s 2023 Employee, Director and Consultant Equity Incentive Plan

	/s/ Jason Grady	11/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)